MEDICINOVA INC
MNOV evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MNOV—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MNOV
Medicinova Inc is a biopharmaceutical company focused on developing novel therapeutics for serious diseases with unmet medical needs, with a commercial focus on the U.S. market and a key upcoming Phase 3 topline readout in 2028.
Key risk: Capital dependency
BioSniper Score
Based on 5 of 6 signals
Market Cap
$70.6M
Cash Runway
39.9 moLead Asset
mn-001 (Phase 2)Next Catalyst
Phase3_Topline · Apr 1, 2028Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 4 clinical trials · 1 catalyst for MEDICINOVA INC.
Medicinova Inc is a biopharmaceutical company focused on developing novel therapeutics for serious diseases with unmet medical needs, with a commercial focus on the U.S. market and a key upcoming Phase 3 topline readout in 2028.
- Medicinova is a biopharmaceutical company focused on developing novel therapeutics for serious diseases with unmet medical needs, with a commercial focus on the U.S. market [sec_mda · as of 2026-03-10].
- As of 2026-06-30, the company reported cash & equivalents of $25.4M, total revenue of $0.5M, net income of -$2.3M, and shareholders' equity of $41.6M [sec].
- The company faces risks including inability to raise additional capital, generate product revenues, or complete clinical trials and obtain regulatory approval [sec_mda · as of 2026-08-13].
- A Phase 3 topline readout is scheduled for 2028-04-01, from a randomized, double-blind, placebo-controlled 12-month clinical trial [upcoming catalysts].
What works
- The company has a focused strategy on novel therapeutics for serious diseases with unmet medical needs, targeting a clear market opportunity [sec_mda · as of 2026-03-10].
- Shareholders' equity of $41.6M as of 2026-06-30 provides a capital base to support ongoing operations and clinical development [sec].
What to weigh
- The company has minimal revenue ($0.5M as of 2026-06-30) and is not yet generating product sales, relying on external capital to fund operations [sec].
- The company faces significant risks including inability to raise additional capital, complete clinical trials, or obtain FDA approval, which could materially affect future results [sec_mda · as of 2026-08-13].
- Net loss of $2.3M as of 2026-06-30 indicates ongoing cash burn without a clear path to profitability [sec].
From the filings
Quoted directly from source documents.
Company focus on novel therapeutics for serious diseases with unmet medical needs
“We are a biopharmaceutical company focused on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market.”
SEC MD&A · March 10, 2026
Risks include inability to raise capital, generate revenues, and complete clinical trials
“Inability to raise additional capital if needed; • Inability to generate revenues from product sales to continue business operations; • Inability to develop and commercialize our product candidates; • Failure or delay in completing clinical trials or obtaining Food and Drug Administration or foreign regulatory approval for our product candidates in a timely manner”
SEC MD&A · August 13, 2026
Catalyst timeline
- 2028-04-01 · Phase3_Topline — Topline results from a Phase 2b/3 randomized, double-blind, placebo-controlled 12-month clinical trial will be reported, providing key efficacy and safety data.
Risks & what to watch (3)›
Key risks
- Capital dependency — Inability to raise additional capital if needed, as the company has minimal revenue and ongoing net losses [sec_mda · as of 2026-08-13].
- Clinical and regulatory failure — Failure or delay in completing clinical trials or obtaining FDA approval for product candidates [sec_mda · as of 2026-08-13].
- Revenue generation risk — Inability to generate revenues from product sales to continue business operations [sec_mda · as of 2026-08-13].
What to watch
- Phase 3 topline readout expected on 2028-04-01, which will be a key determinant of the company's clinical and regulatory trajectory [upcoming catalysts].
- Cash runway and ability to raise additional capital, given the company's net loss and limited revenue [sec].
- Any updates on FDA interactions or regulatory milestones for the lead candidate [sec_mda · as of 2026-08-13].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run MEDICINOVA INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MEDICINOVA INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
39.9 months
D/E 0.08 · 0% dilution
Lead: Phase 1/Phase 2
4 candidates
1 upcoming, next in ~580d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
29
Total value held
$7.9M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,222,078 | $1.7M |
| essex woodlands management, inc. | 1,105,941 | $1.5M |
| blackrock, inc. | 705,954 | $967K |
| citigroup inc | 635,715 | $871K |
| geode capital management, llc | 543,843 | $745K |
| vanguard fiduciary trust co | 280,621 | $384K |
| state street corp | 193,698 | $265K |
| renaissance technologies llc | 189,900 | $260K |
| barclays plc | 162,900 | $223K |
| northern trust corp | 133,163 | $182K |
Showing top 10 of 29 institutional holders of MEDICINOVA INC. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 0.4%
- Days to cover
- 6.3
- Shares short
- 172,326
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MNOV short interestGovernance
Frequently asked questions
What is the AI investment thesis for MEDICINOVA INC?
Medicinova Inc is a biopharmaceutical company focused on developing novel therapeutics for serious diseases with unmet medical needs, with a commercial focus on the U.S. market and a key upcoming Phase 3 topline readout in 2028.
What is MEDICINOVA INC's lead drug candidate?
MEDICINOVA INC's most advanced tracked candidate is mn-001 (Phase 2) for Diabetes Mellitus, Type 2; Idiopathic Pulmonary Fibrosis.
What is MEDICINOVA INC's next catalyst?
MEDICINOVA INC's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to" — expected April 1, 2028.
Who is the CEO of MEDICINOVA INC?
Dr. Yuichi Iwaki M.D., Ph.D. is the chief executive officer of MEDICINOVA INC (MNOV).
Where is MEDICINOVA INC headquartered?
MEDICINOVA INC (MNOV) is headquartered in La Jolla, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.